SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 5 analyzed stories

MRNA: Higher revenue guidance and positive Phase 3 melanoma results mark a stronger quarter

Moderna reported that third-quarter revenue rose 29% year over year to $1.313 billion and net income was $162 million, compared with a loss a year earlier. It raised its 2026 revenue growth guidance to 15–25% and said intismeran produced positive Phase 3 melanoma results.

Published:

Updated:

What happened

Moderna reported third-quarter revenue of $1.313 billion, up 29% from a year earlier, and net income of $162 million. It raised its 2026 revenue growth outlook to 15%–25%. Its norovirus trial missed interim early-success criteria, while its mFLUSIVA vaccine was approved and melanoma trial results were positive.

Global impact / market context

Higher revenue and a raised outlook may support confidence in Moderna’s business. The norovirus setback is a counterpoint. For ordinary investors, the mixed results leave uncertainty about how its products and future revenue will develop.

What to watch

  1. Check Moderna’s next revenue update to see whether growth continues and how it compares with the raised outlook.
  2. Check for further information on the norovirus trial, because it missed interim early-success criteria.
  3. Check for further updates on mFLUSIVA approval and melanoma results, because these were positive developments.

Affected assets

  • Moderna, Inc.

Evidence